Temelimab, an IgG4 Anti-Human Endogenous Retrovirus Monoclonal Antibody: An Early Development Safety Review

A Safety and Pharmacodynamics Study of Temelimab, an anti‐HERV‐W‐Env Monoclonal Antibody, in Type 1 Diabetes Patients

(2020) Francois Curtin et al.   DIABETES OBESITY & METABOLISM

A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env

(2019) Hervé Porchet et al.   CLINICAL THERAPEUTICS

Human Endogenous Retroviruses and Type 1 Diabetes

(2019) Sandrine Levet et al.   Current Diabetes Reports

A new therapeutic approach for type 1 diabetes: Rationale for GNbAC1, an anti-HERV-W-Env monoclonal antibody

(2018) Francois Curtin et al.   DIABETES OBESITY & METABOLISM

Human Endogenous Retroviruses in Neurological Diseases

(2018) Patrick Küry et al.   TRENDS IN MOLECULAR MEDICINE

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease

(2018) Joseph Jankovic et al.   JAMA Neurology

Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: A Phase 1 study

(2016) François Curtin et al.   mAbs

A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis – Rationale and design

(2016) Francois Curtin et al.   Multiple Sclerosis and Related Disorders

Human Endogenous Retrovirus and Neuroinflammation in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

(2016) Raphaël Faucard et al.   EBioMedicine

A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients — A twelve month follow-up

(2015) Tobias Derfuss et al.   JOURNAL OF NEUROIMMUNOLOGY

Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein

(2014) François Curtin et al.   mAbs

Human Endogenous Retrovirus Protein Activates Innate Immunity and Promotes Experimental Allergic Encephalomyelitis in Mice

(2013) Hervé Perron et al.   PLoS One

Novel therapeutic options for multiple sclerosis

(2013) François Curtin et al.   Expert Review of Clinical Pharmacology

GNbAC1, a Humanized Monoclonal Antibody Against the Envelope Protein of Multiple Sclerosis—Associated Endogenous Retrovirus: A First-in-Humans Randomized Clinical Study

(2012) François Curtin et al.   CLINICAL THERAPEUTICS

Epigenetic regulation of transcription and splicing of syncytins, fusogenic glycoproteins of retroviral origin

(2011) Kateřina Trejbalová et al.   NUCLEIC ACIDS RESEARCH

Inflammation, demyelination, and degeneration — Recent insights from MS pathology

(2010) Christine Stadelmann et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

The Human Endogenous Retrovirus Link between Genes and Environment in Multiple Sclerosis and in Multifactorial Diseases Associating Neuroinflammation

(2009) Hervé Perron et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY